Servier says its next IDH inhibitor has passed PhIII, but no regulatory timeline yet
Servier’s IDH inhibitor vorasidenib has passed its Phase III trial in low-grade glioma, the company announced Tuesday morning. However, it left its regulatory timeline up in the air.
The drug met the primary endpoint of progression-free survival as well as a secondary endpoint of time to next intervention, Servier said. But when asked for more details in an interview with Endpoints News, Servier’s VP of clinical development Susan Pandya declined to comment.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.